Linked Life Data

1861071

Source:http://linkedlifedata.com/resource/pubmed/id/1861071

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1991-8-30
pubmed:abstractText
Previous studies have shown that the mouse antiidiotypic mAb MK2-23 elicited with the syngeneic anti-human high molecular weight melanoma-associated Ag (HMW-MAA) mAb 763.74 elicits anti-HMW-MAA antibodies in syngeneic hosts and in patients with melanoma. The present investigation has characterized the fine specificity of antibodies elicited by mAb MK2-23, tested its ability to induce delayed-type hypersensitivity reaction to HMW-MAA-bearing melanoma cells and analyzed the variables that influence the immunogenicity of mAb MK2-23. The anti-HMW-MAA antibodies elicited by mAb MK2-23 recognize the same population of molecules recognized by mAb 763.74, react with the same (or spatially close) determinant(s) and express the idiotopes recognized by mAb MK2-23 in their Ag-combining sites. The antiidiotypic antibodies that bind to HMW-MAA have a lower titer than those that do not. These results in conjunction with those obtained in mice using a suboptimal immunization schedule suggest that the idiotope(s) that mimic(s) the mAb 763.74-defined determinant of the HMW-MAA is less immunogenic than those that do not. mAb MK2-23 induces a delayed-type hypersensitivity reaction to HMW-MAA-bearing melanoma cells. Therefore, mAb MK2-23 represents the first example of mouse antiidiotypic mAb that induces a cellular and humoral immunity to a human tumor-associated Ag (TAA), because the previously described mouse antiidiotypic mAb that bear the mirror image of TAA have been shown to induce only humoral anti-TAA immunity. The immunogenicity of mAb MK2-23 is markedly enhanced by its conjugation to keyhole limpet hemocyanin and its administration with FA. Furthermore, the number of immunizations and the doses of mAb MK2-23 injected influence its immunogenicity, although to a lower extent than conjugation to a carrier and mixing with an adjuvant. The information derived from the present investigation represents a useful background to optimize the immunization schedule with mAb MK2-23 in patients with melanoma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
147
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1082-90
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:1861071-Animals, pubmed-meshheading:1861071-Antibodies, Anti-Idiotypic, pubmed-meshheading:1861071-Antibodies, Monoclonal, pubmed-meshheading:1861071-Antibody Formation, pubmed-meshheading:1861071-Antibody Specificity, pubmed-meshheading:1861071-Antigens, Neoplasm, pubmed-meshheading:1861071-Dose-Response Relationship, Immunologic, pubmed-meshheading:1861071-Electrophoresis, Polyacrylamide Gel, pubmed-meshheading:1861071-Freund's Adjuvant, pubmed-meshheading:1861071-Hemocyanin, pubmed-meshheading:1861071-Hypersensitivity, Delayed, pubmed-meshheading:1861071-Immunotherapy, pubmed-meshheading:1861071-Immunotoxins, pubmed-meshheading:1861071-Melanoma, pubmed-meshheading:1861071-Melanoma-Specific Antigens, pubmed-meshheading:1861071-Mice, pubmed-meshheading:1861071-Mice, Inbred BALB C, pubmed-meshheading:1861071-Neoplasm Proteins, pubmed-meshheading:1861071-Tumor Cells, Cultured
pubmed:year
1991
pubmed:articleTitle
Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts.
pubmed:affiliation
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't